Advertisement
News
Subscribe to MDT Magazine News

Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting

March 28, 2011 5:35 am | by Bio-Medicine.Org | Comments

NEW YORK, March 28, 2011 /- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) (the "Company") today announced that two abstracts on KRX-0401 (perifosine) will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research (AACR) to be held in Orlando,...

TOPICS:

Interventional radiologists take lead on reducing disability from dangerous blood clots

March 28, 2011 5:33 am | by EurekAlert | Comments

(Society of Interventional Radiology) Deep vein thrombosis, or DVT: it's more than just a one-time complication from taking a long plane ride. The Society of Interventional Radiology wants individuals to know the risk factors for this very serious condition, which can lead to...

TOPICS:

Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality

March 28, 2011 5:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 28, 2011 /- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of...

TOPICS:
Advertisement

Quest Diagnostics Commences Tender Offer for Acquisition of Celera

March 28, 2011 5:32 am | by Bio-Medicine.Org | Comments

MADISON, N.J., March 28, 2011 /- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the...

TOPICS:

Graymark Healthcare Reports Full Year 2010 Results

March 28, 2011 5:32 am | by Bio-Medicine.Org | Comments

OKLAHOMA CITY, March 28, 2011 /- Graymark Healthcare, Inc. (Nasdaq: GRMH ), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), reported financial results for the fiscal year ended December 31, 2010....

TOPICS:

SpaceClaim Engineer 2010 Chosen as a Best Product in Design Tools

March 28, 2011 4:45 am | by The Associated Press | Comments

SpaceClaim (http://www.spaceclaim.com/) , the leader in direct modeling software that enables all engineers to work in 3D, today announced that it has won a Design News Golden Mousetrap Award for product innovation and creativity.The Golden Mousetrap was awarded to SpaceClaim for...

Pharmasset to Webcast an Investor Event From the EASL Meeting

March 28, 2011 4:37 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., March 28, 2011 /- Pharmasset, Inc. (Nasdaq: VRUS ) today announced that it will webcast an investor event from the European Association for the Study of the Liver (EASL) on Saturday, April 2, 2011 starting at 8:00pm CET. During this webcast, management will review...

TOPICS:

Prometheus Finds Profits in Pharmaceuticals

March 28, 2011 4:35 am | by San Diego Business Journal | Comments

Prometheus Inc., the Sorrento Valley-based drug and diagnostics development company, reported its 10th profitable year in a row, according to a news release.

TOPICS:
Advertisement

Interventional radiology treatment takes blood pressure to new lows -- and results last

March 28, 2011 4:34 am | by EurekAlert | Comments

(Society of Interventional Radiology) Interventional radiologists have completed the first human randomized controlled trial of a procedure that uses high-frequency energy to deactivate the nerves near the kidneys (or in the renal artery) that are linked to high blood pressure. These...

TOPICS:

Adeona's Multiple Sclerosis Trial Receives $409,426 Grant

March 28, 2011 3:34 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., March 28, 2011 /- Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta™ (oral estriol) drug candidate has received an additional...

TOPICS:

Adeona to Host 2010 Year End Investor Conference Call

March 28, 2011 3:34 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., March 28, 2011 /- Adeona Pharmaceuticals, Inc. (Amex: AEN ), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 2010 year end investor conference call on Thursday, March 31, 2011, at 4:30pm EDT. James S....

TOPICS:

Health Care Reforms Slow to Impact Real Estate

March 27, 2011 11:35 pm | by San Diego Business Journal | Comments

A year after landmark national health care reforms were signed into law, local observers say the impact on medical-related real estate has yet to be seen on a large scale.

TOPICS:

Dental Biotech Firm Departs With a Smile

March 27, 2011 11:33 pm | by San Diego Business Journal | Comments

After finding a buyer for its only product, local dental biotech company Novalar Pharmaceuticals Inc. will cease operations at the end of the month.

TOPICS:

Certain breast cancer patients worry excessively about recurrence

March 27, 2011 9:38 pm | by EurekAlert | Comments

(Wiley-Blackwell) A new study has found that certain types of women with early stage breast cancer are vulnerable to excessive worrying about cancer recurrence. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study also indicates that...

TOPICS:

Study finds changes in incidence of end-stage renal disease from lupus nephritis

March 27, 2011 9:32 pm | by EurekAlert | Comments

(Wiley-Blackwell) New research documenting changes in the incidence and outcomes of end-stage renal disease (ESRD) in the US between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans. A second related study revealed...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading